Comment on

• Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.

  Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, Fergus S, Trovo M, Bradley JD, Robinson CG. Speirs CK, et al. J Thorac Oncol. 2017 Feb;12(2):293-301. doi: 10.1016/j.jtho.2016.09.134. Epub 2016 Oct 12. J Thorac Oncol. 2017. PMID: 27743888 Clinical Trial.
• Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

  Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, Mavroidis P, Lee CB, Jensen BC, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB. Wang K, et al. J Clin Oncol. 2017 May 1;35(13):1387-1394. doi: 10.1200/JCO.2016.70.0229. Epub 2017 Jan 23. J Clin Oncol. 2017. PMID: 28113017 Free PMC article. Clinical Trial.
• Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.

  Dess RT, Sun Y, Matuszak MM, Sun G, Soni PD, Bazzi L, Murthy VL, Hearn JWD, Kong FM, Kalemkerian GP, Hayman JA, Ten Haken RK, Lawrence TS, Schipper MJ, Jolly S. Dess RT, et al. J Clin Oncol. 2017 May 1;35(13):1395-1402. doi: 10.1200/JCO.2016.71.6142. Epub 2017 Mar 16. J Clin Oncol. 2017. PMID: 28301264 Free PMC article. Clinical Trial.
• Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.

  Guberina M, Eberhardt W, Stuschke M, Gauler T, Heinzelmann F, Cheufou D, Kimmich M, Friedel G, Schmidberger H, Darwiche K, Jendrossek V, Schuler M, Stamatis G, Pöttgen C. Guberina M, et al. Ann Oncol. 2017 May 1;28(5):1084-1089. doi: 10.1093/annonc/mdx069. Ann Oncol. 2017. PMID: 28453703 Clinical Trial.